Paul M Cinciripini1, Jennifer A Minnix1, Charles E Green2, Jason D Robinson1, Jeffrey M Engelmann3, Francesco Versace1, David W Wetter4, Sanjay Shete1, Maher Karam-Hage1. 1. Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Pediatrics, Center for Clinical Research and Evidence-Based Medicine, The University of Texas at Houston Health Sciences Center, Houston, TX, USA. 3. Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 4. Department of Population Health Sciences and the Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Abstract
BACKGROUND AND AIMS: Despite the availability of several efficacious smoking cessation treatments, fewer than 25% of smokers who quit remain abstinent 1 year post-treatment. This study aimed to determine if varenicline and bupropion combination treatment would result in higher abstinence rates than varenicline alone. DESIGN: A double-blind, randomized, parallel-group smoking cessation clinical trial in which participants were exposed to 12 weeks of treatment and followed for 12 months. SETTING:Hospital-based out-patient clinic in Texas, USA specializing in cancer prevention. PARTICIPANTS: A total of 385 community smokers (58.44% male) who smoked 1 pack of cigarettes/day [mean = 19.66 cigarettes/day, standard deviation (SD) = 9.45]; had average carbon monoxide (CO) of 26.43 parts per million (SD = 13.74); and were moderately dependent (Fagerström Test for Cigarette Dependence = 4.79; SD = 2.07). INTERVENTIONS AND COMPARATOR: Smokers were randomized in a 3 : 1 (active: Placebo) ratio to 12 weeks of treatment as follows: placebo (n = 56), varenicline (Var; n = 166), and varenicline + bupropion (Combo; n = 163). MEASUREMENTS: A priori primary outcome: prolonged abstinence at 12 months. SECONDARY OUTCOMES: 7-day point prevalence abstinence and continuous abstinence; all abstinence measures at end of treatment and 6-month follow-ups. FINDINGS:Intention-to-treat analysis: the Combo group (n = 163) failed to demonstrate superiority to the Var group (n = 166) for prolonged abstinence at 12 months [odds ratio (OR) = 0.91, 95% confidence interval (CI) = 0.50-1.64], supported by Bayes factor = 0.06. Both the Var (OR = 6.66, 95% CI = 1.61-59.27) and Combo groups (OR = 6.06, 95% CI = 1.45-54.09) demonstrated superiority to the Placebo group (n = 56; score = 8.38, P < 0.016). CONCLUSIONS: The addition of bupropion to varenicline treatment does not appear to increase smoking abstinence rates above that of varenicline alone. The findings support previous research showing a consistently favorable effect of both varenicline and the combination of varenicline and bupropion on smoking cessation compared with placebo.
RCT Entities:
BACKGROUND AND AIMS: Despite the availability of several efficacious smoking cessation treatments, fewer than 25% of smokers who quit remain abstinent 1 year post-treatment. This study aimed to determine if varenicline and bupropioncombination treatment would result in higher abstinence rates than varenicline alone. DESIGN: A double-blind, randomized, parallel-group smoking cessation clinical trial in which participants were exposed to 12 weeks of treatment and followed for 12 months. SETTING: Hospital-based out-patient clinic in Texas, USA specializing in cancer prevention. PARTICIPANTS: A total of 385 community smokers (58.44% male) who smoked 1 pack of cigarettes/day [mean = 19.66 cigarettes/day, standard deviation (SD) = 9.45]; had average carbon monoxide (CO) of 26.43 parts per million (SD = 13.74); and were moderately dependent (Fagerström Test for Cigarette Dependence = 4.79; SD = 2.07). INTERVENTIONS AND COMPARATOR: Smokers were randomized in a 3 : 1 (active: Placebo) ratio to 12 weeks of treatment as follows: placebo (n = 56), varenicline (Var; n = 166), and varenicline + bupropion (Combo; n = 163). MEASUREMENTS: A priori primary outcome: prolonged abstinence at 12 months. SECONDARY OUTCOMES: 7-day point prevalence abstinence and continuous abstinence; all abstinence measures at end of treatment and 6-month follow-ups. FINDINGS: Intention-to-treat analysis: the Combo group (n = 163) failed to demonstrate superiority to the Var group (n = 166) for prolonged abstinence at 12 months [odds ratio (OR) = 0.91, 95% confidence interval (CI) = 0.50-1.64], supported by Bayes factor = 0.06. Both the Var (OR = 6.66, 95% CI = 1.61-59.27) and Combo groups (OR = 6.06, 95% CI = 1.45-54.09) demonstrated superiority to the Placebo group (n = 56; score = 8.38, P < 0.016). CONCLUSIONS: The addition of bupropion to varenicline treatment does not appear to increase smoking abstinence rates above that of varenicline alone. The findings support previous research showing a consistently favorable effect of both varenicline and the combination of varenicline and bupropion on smoking cessation compared with placebo.
Authors: Jon O Ebbert; Dorothy K Hatsukami; Ivana T Croghan; Darrell R Schroeder; Sharon S Allen; J Taylor Hays; Richard D Hurt Journal: JAMA Date: 2014-01-08 Impact factor: 56.272
Authors: Aimee L McRae-Clark; Nathaniel L Baker; Susan C Sonne; C Lindsay DeVane; Amanda Wagner; Jessica Norton Journal: J Subst Abuse Treat Date: 2015-05-07
Authors: Kenneth A Perkins; Joshua L Karelitz; Nancy C Jao; Ruben C Gur; Caryn Lerman Journal: Drug Alcohol Depend Date: 2013-05-31 Impact factor: 4.492
Authors: Timothy B Baker; Megan E Piper; James H Stein; Stevens S Smith; Daniel M Bolt; David L Fraser; Michael C Fiore Journal: JAMA Date: 2016-01-26 Impact factor: 56.272
Authors: Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins Journal: Lancet Date: 2016-04-22 Impact factor: 79.321
Authors: Jason D Robinson; Yong Cui; Paulina Linares Abrego; Jeffrey M Engelmann; Alexander V Prokhorov; Damon J Vidrine; Sanjay Shete; Paul M Cinciripini Journal: Psychol Addict Behav Date: 2022-01-13